Cargando…
β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial
A feasibility randomised controlled trial of β-blockers in acute exacerbations of COPD http://ow.ly/lVcy305B36D
Autores principales: | Chang, Catherina L., Wong, Conroy, Beckert, Lutz, Shafuddin, Eskandarain, Beasley, Richard, Young, Robert, Hancox, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279067/ https://www.ncbi.nlm.nih.gov/pubmed/28154818 http://dx.doi.org/10.1183/23120541.00090-2016 |
Ejemplares similares
-
Cardiac biomarkers and long-term outcomes of exacerbations of COPD: a long-term follow-up of two cohorts
por: Shafuddin, Eskandarain, et al.
Publicado: (2021) -
MULTI-PHACET: multidimensional clinical phenotyping of hospitalised acute COPD exacerbations
por: MacDonald, Martin I., et al.
Publicado: (2021) -
A case report describing the use of systemic bevacizumab in the treatment of recurrent respiratory papillomatosis with pulmonary involvement
por: O'Brien, Amy, et al.
Publicado: (2023) -
The safety of cardioselective β(1)-blockers in asthma: literature review and search of global pharmacovigilance safety reports
por: Bennett, Miriam, et al.
Publicado: (2021) -
A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease
por: Shafuddin, Eskandarain, et al.
Publicado: (2015)